Nonprofit sues FDA to force Provenge approval

Share this article:
A nonprofit patient advocacy group has filed suit against the FDA in an Ohio federal court seeking to overturn the agency's decision earlier this year to not approve Dendreon's prostate cancer vaccine Provenge.

The lawsuit, filed by Ohio-based Care to Live, which includes some Dendreon investors, alleges that the FDA in May failed to follow an advisory committee recommendation to approve Provenge and instead asked the company for more information.

The group argues that Provenge's Biologics License Application approval was derailed by Richard Pazdur, director of the FDA drug center's oncologic drugs division, as part of a bureaucratic turf battle with the FDA's biologics center over who would control all oncology therapies.

It charges that this led him to place two conflicted panel members on an advisory committee that reviewed the drug.

The suit also alleges that FDA commissioner Andrew von Eschenbach was in support of an earlier biologics center recommendation to approve Provenge, but instead gave in to Pazdur's demands after he “executed a successful coup d'etat.”

Share this article:

Email Newsletters

More in News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...